Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Rectal Cancer. According to GlobalData, Phase II drugs for Rectal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Etrumadenant LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Etrumadenant overview
AB-928 is under development for the treatment of solid tumors including bladder cancer, rectal cancer, endometrial cancer, head and neck squamous cell carcinoma, melanoma, Merkel cell carcinoma, pancreatic ductal adenocarcinoma, metastatic ovarian cancer, metastatic gastroesophageal cancer, colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. The drug candidate is administered orally. It acts by targeting adenosine receptor 2a and adenosine receptor 2b.
The drug was under development for the treatment of metastatic castration-resistant prostate cancer and metastatic triple negative breast cancer.
Arcus Biosciences overview
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer, ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. Arcus Biosciences is headquartered in Hayward, California, the US.
For a complete picture of Etrumadenant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
